Alterations in calcium handling in cardiac hypertrophy and heart failure

C W Balke1, S R Shorofsky

  • 1Department of Physiology, University of Maryland School of Medicine, Baltimore 21201, USA. bbalke@heart.ab.umd.edu

Insights

Conflicting data on cardiac hypertrophy and heart failure effects on calcium handling exist due to varied models and disease stages. Longitudinal studies in well-matched animal models are crucial for understanding excitation-contraction coupling abnormalities.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Physiology

Background:

  • Conflicting data exists regarding L-type Ca2+ channel density, intracellular Ca2+ transients, and Ca2+ sparks in cardiac hypertrophy and failure.
  • Discrepancies stem from model-dependent effects, varied disease generation mechanisms, non-uniform disease distribution, and disease progression stage.

Purpose of the Study:

  • To address discrepancies in understanding cardiac hypertrophy and failure effects on calcium handling.
  • To highlight the need for standardized, longitudinal animal models for studying cardiac disease progression.

Main Methods:

  • Review and analysis of existing data on cardiac hypertrophy and failure.
  • Discussion of challenges in comparing results across different animal models and disease stages.

Main Results:

  • Cardiac hypertrophy increases myocardial contractility, while heart failure decreases it, complicating direct comparisons.
  • L-type Ca2+ channel behavior and SR function are dependent on the extent of disease expression.

Conclusions:

  • Consistent data requires longitudinal studies using a single, well-characterized animal model that mimics human disease.
  • Improved Ca2+ imaging and understanding of excitation-contraction coupling are vital for identifying abnormalities and defining treatments.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...